Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

the quarter ended June 30, 2012. The increase in revenue was primarily due to the Company earning a $50 million milestone payment during the quarter ended June 30, 2013 under its collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen"). The $50 million milestone was earned on April 11, 2013 as a result of the enrollment of a fifth patient in a study using ibrutinib (PCI-32765) as a monotherapy versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Revenue for the six months ended June 30, 2013 was $57.5 million, compared to $4.1 million for the six months ended June 30, 2012.

To date, the Company has received four milestone payments from Janssen of $50 million each, totaling $200 million, under the Agreement. The Company may receive up to an additional $625 million ($50 million for development progress, $225 million for regulatory progress, and $350 million for regulatory approval) in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general, Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year.

GAAP operating expenses were $42.7 million for the quarter ended June 30, 2013, compared to $19.6 million for the quarter ended June 30, 2012. During the three months ended June 30, 2013, the Company exceeded the $50 million annual cap on the Company's share of development costs and pre-tax commercialization losses by $20.4 million. The Company reco
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Animal Health Market 2014-2018 ... Animal Health Animal health refers to veterinary services ... to enhance their quality of life, increase their ... The Global Animal Health market covers the following ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com ... report is available in its catalogue: ... Application and Approval of Imported Medical ... (2014 Edition) ... Now, Chinese regulations on medical devices ...
(Date:8/27/2014)... Calif. , Aug. 27, 2014 Amgen ... Food and Drug Administration (FDA) has granted priority review ... failure (HF). Ivabradine is an oral drug that inhibits ... in the sinoatrial node, the body,s cardiac pacemaker. 1 ... negative effects on myocardial contractility or ventricular repolarization. 1 ...
Breaking Medicine Technology:Global Animal Health Market 2014-2018 2Global Animal Health Market 2014-2018 3Global Animal Health Market 2014-2018 4Global Animal Health Market 2014-2018 5Global Animal Health Market 2014-2018 6Global Animal Health Market 2014-2018 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... , , ... 19 Newly published data in The New England Journal ... following surgery as an optimal treatment approach versus tamoxifen for postmenopausal ... The data include an analysis from the Breast International ...
... MOFFETT FIELD, Calif., Aug. 19 Humans might ... ancient fusing of two microscopic, single-celled organisms called prokaryotes, NASA-funded ... http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ) , , By comparing proteins ... of single-celled organism without a nucleus -- molecular biologist James ...
Cached Medicine Technology:Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 2Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 3Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 4Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 5Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 6Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 7Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 8Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 9NASA Research Reveals Major Insight Into Evolution of Life on Earth 2
(Date:8/27/2014)... August 27, 2014 Power morcellator lawsuits ... courts on behalf of women who allegedly experienced the ... Liebhard LLP reports. According to court documents, one of ... in the U.S. District Court, Northern District of New ... the use of a power morcellator manufactured Karl Storz ...
(Date:8/27/2014)... August 27, 2014 Picture, if you will, ... and Watson but more of a Mr. Inside, a Doc ... terms of personalities and world view. This Mr. Inside was ... Texas at Austin, and Mr. Outside was an Austin Police ... his new girlfriend, and a gaggle of teenagers embarked on ...
(Date:8/27/2014)... August 27, 2014 When Jagger was 20 ... from his mother; one that he credits as one of ... mom had news that she could set him up with ... with disabilities. Jagger took that job, and he has now ... these past two decades, he also worked in school boards, ...
(Date:8/27/2014)... 2014 The newest Abington Health ... September 8, 2014. This new 15,000 square foot, $5 ... primary care practices and walk-in laboratory services. ... exciting endeavor for Abington Health as the healthcare landscape ... Health. “Establishing a location in Lower Gwynedd allows us ...
(Date:8/27/2014)... Amy Norton HealthDay Reporter ... who take part in clinical trials of new heart disease ... patient, a new study confirms. Experts said the findings, ... American Medical Association , aren,t surprising -- but they are ... enrolling a more select patient population that is not fully ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 4Health News:UW Rankin Self-Publishes Debut Novel, Sublimity: Perchance to Dream, A Speculative Science Mystery 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 3Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 4Health News:Abington Health Opens New Health Center in Lower Gwynedd 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3
... rheumatoid arthritis (RA), an autoimmune disease marked by chronic ... and the incidence of cancer is complicated. Epidemiologic ... cancers are increased among RA patients, while breast and ... are caused by the nature of RA or by ...
... for downward social mobility, study confirms , , TUESDAY, Aug. ... a downscale neighborhood often go together, a new study ... comes first. , "The more alcohol problems a man ... in, or migrate into, a disadvantaged neighborhood," according to ...
... report cites drop in employer-sponsored coverage , , TUESDAY, ... Americans are without health insurance, according to new U.S. ... trend can be explained by employers who are curtailing ... workers to afford, the report said. , "The number ...
... better diagnoses and therapies, researchers say , , TUESDAY, Aug. ... the brains of multiple sclerosis patients may help predict ... researchers are reporting. , "This is a new ... the tissue of the patient,s lesions," said lead researcher ...
... age 7 were virtually erased, study finds , , TUESDAY, ... during pregnancy and don,t get treatment, their kids face ... suggests that treatment can essentially eliminate that risk. , ... obesity can be completely reversed in these children, said ...
... to be published in an upcoming edition of ... that Pycnogenol (pic-noj-en-all), pine bark extract from the ... as hot flashes, depression, panic attacks, cholesterol and ... transition. The results suggest Pycnogenol may serve as ...
Cached Medicine News:Health News:Biologic treatment for rheumatoid arthritis and the risk of cancer 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 3Health News:Record Number of Americans Lack Health Insurance 2Health News:Record Number of Americans Lack Health Insurance 3Health News:Record Number of Americans Lack Health Insurance 4Health News:Brain Lesions Predict MS Progression 2Health News:Brain Lesions Predict MS Progression 3Health News:Treating Diabetes During Pregnancy Could Lead to Thinner Kids 2Health News:New study: Pine bark reduces perimenopausal symptoms 2
Open wire style 16 mm blade with a wing tip twist giving the surgeon better on-axis accessibility....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: